Patients in the non-exposure group were older (60.7 ± 13.3 years vs. 51.9 ± 10.9 years, p < 0.001), less commonly men (74.9% vs. 92.0%, p = 0.001), had higher hypertension (64.8% vs. 42.7%, p < 0.001) and type 2 diabetes (28.1% vs. 16.0%, p = 0.030) rates, and less commonly took methotrexate (11.2% vs. 28.0%, p < 0.001), sulfasalazine (38.2% vs. 73.3%, p < 0.001), and selective COX-2 inhibitors (59.8% vs. 72.0%, p = 0.048) than those in the exposure group. This evidence concerns the gene PTGS2 and hypertensive disorder.